Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Cedazuridine and Decitabine by in Bulk and its Pharmaceutical Dosage Form
Main Article Content
Abstract
Objective: A new sensitive accurate and precise reverse-phase high-performance liquid chromatography
(RP-HPLC) method was developed for the simultaneous estimation of cedazuridine and decitabine in bulk and
pharmaceutical formulation. Materials and Methods: Chromatographic separation was achieved through Altima
C18 column (4.6*150 nm, 5 μm) using 0.01 Kh2PO4:acetonitrile (60:40 v/v) mixture used as the mobile phase.
The Waters 2695, Reciprocating Water-510 pump system with PDA detector, and EMPOWERPRO software
were monitored at detection wavelength 257 nm on flow rate 1 mL/min and the method was validated as per
ICH guidelines (ICH,Q2 [R1]). Results and Discussion: Cedazuridine and decitabine were eluted at 2.248 min
and 2.956 min, respectively, with good resolution. Plate count and tailing factor were very satisfactory, so this
method was optimized and to be validated. Conclusion: This RP-HPLC method was successfully applied for the
simultaneous determination of cedazuridine and decitabine in their pharmaceutical formulation and, hence, can be
used for the routine analysis of these drugs in combined dosage form.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.